Is there a role at this time for chemo-immunotherapy in the upfront treatment of classic Hodgkin lymphoma?
Although not approved, for example, are you every using AVD-nivolumab?
Answer from: Medical Oncologist at Community Practice
Immune checkpoint inhibitors plus AVD is an active area of investigation in frontline treatment of cHL. We have clinical trials which study this combo in context of PET directed dose escalation. NCT03033914
Sign in or Register to read more